Global Bacteriophages Therapy Market

Bacteriophages Therapy Comprehensive Study by Type (Lytic, Lysogenic), Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Treatment (Oral, External Application, Surgical Treatment), Specifications (Human Medicine, Veterinary Science, Agriculture), End User (Hospitals & Clinics, Academic Research Organizations & Institutes, Others) Players and Region - Global Market Outlook to 2028

Bacteriophages Therapy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Bacteriophages therapy is also called as phage therapy. The Bacteriophages therapy comes from science in which Bacteriophage means “bacteria eater” they are seen in soil, sewage, water, and other places bacteria live. Phage therapy used to treat bacterial infections. Its main use may be as an alternative to antibiotics when bacteria develop resistance. It has approved first clinical trial from FDA recently.This growth is primarily driven by Growing need for therapeutic Bacteriophages therapy they have advantages over antibiotics .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Armata Pharmaceuticals, Inc (United States), iNtODEWORLD, Inc (United States), Phage International, Inc (United States), Fixed-Phage Limited (United Kingdom), LOCUS BIOSCIENCES, INC (United States), Pherecydes Pharma (French), Adaptive Phage Therapeutics (United States), Intralytix, Inc (United States), PhagoMed Biopharma GmbH (Austria) and PHAGELUX, INC (China), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 5th September 2019, iNtRON announced that it will be collaborating with Estech Pharma for its eHeme development. The iNtRON Biotechnology and Estech Pharma today announced that they having collaboration with Estech Pharma on eHeme (engineered Heme) technology development. They will introduce new joint venture for further process.
On 12th September Armata Pharmaceuticals announced its development in New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa. Recently Company announced that it has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa (also referred to herein as "Pseudomonas" or "P. aeruginosa") to treat patients with serious respiratory infections.The growing new therapies market increasing demand for bacteriophages therapy .The potential demand for alternative treatment on antibiotic is bacteriophage treatments .The top leading firms working on their research teams to develop clinical trial and get approval from FDA for market use of that particular trial. Also, an open option of mergers and acquisitions to enhance the business equations in the markets.

Regulatory Insights:
The FDA has not yet approved the bacteriophage-based therapy it has only cleared its first clinical trial .Also, Phage therapy is being used in the food industry, as U.S. Food and Drug Administration (FDA) has approved of some phage mixtures to help stop and reduce bacteria from growing in foods. Phage therapy in food prevents bacteria that can cause food poisoning; it will be great advantage for food industry.

Influencing Trend:
Growing research studies and ongoing clinical trials for same

Market Growth Drivers:
Growing need for therapeutic Bacteriophages therapy they have advantages over antibiotics and Potent used in various treatments as they directly target disease-causing bacteria

Challenges:
Not yet approved by FDA IN countries like United States or in Europe and High cost associated with treatment

Restraints:
Bacteriophages therapy not yet adopted and are not yet widely used

Opportunities:
Bacteriophages therapies are highly used in Russia, Georgia and Poland, Russia, extensive research and development soon began in this field and Best option available for processed foods to help prevent bacterial growth

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Bacteriophages Therapy Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Bacteriophages Therapy Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Bacteriophages Therapy players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Bacteriophages Therapy Study Sheds Light on
— The Bacteriophages Therapy Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Bacteriophages Therapy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Bacteriophages Therapy industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Lytic
  • Lysogenic
By Application
  • Diagnostic
  • Antimicrobial Drug Discovery
  • Veterinary Medicines
  • Others
By Treatment
  • Oral
  • External Application
  • Surgical Treatment

By Specifications
  • Human Medicine
  • Veterinary Science
  • Agriculture

By End User
  • Hospitals & Clinics
  • Academic Research Organizations & Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing need for therapeutic Bacteriophages therapy they have advantages over antibiotics
      • 3.2.2. Potent used in various treatments as they directly target disease-causing bacteria
    • 3.3. Market Challenges
      • 3.3.1. Not yet approved by FDA IN countries like United States or in Europe
      • 3.3.2. High cost associated with treatment
    • 3.4. Market Trends
      • 3.4.1. Growing research studies and ongoing clinical trials for same
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bacteriophages Therapy, by Type, Application, Treatment, Specifications, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Bacteriophages Therapy (Value)
      • 5.2.1. Global Bacteriophages Therapy by: Type (Value)
        • 5.2.1.1. Lytic
        • 5.2.1.2. Lysogenic
      • 5.2.2. Global Bacteriophages Therapy by: Application (Value)
        • 5.2.2.1. Diagnostic
        • 5.2.2.2. Antimicrobial Drug Discovery
        • 5.2.2.3. Veterinary Medicines
        • 5.2.2.4. Others
      • 5.2.3. Global Bacteriophages Therapy by: Treatment (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. External Application
        • 5.2.3.3. Surgical Treatment
      • 5.2.4. Global Bacteriophages Therapy by: Specifications (Value)
        • 5.2.4.1. Human Medicine
        • 5.2.4.2. Veterinary Science
        • 5.2.4.3. Agriculture
      • 5.2.5. Global Bacteriophages Therapy by: End User (Value)
        • 5.2.5.1. Hospitals & Clinics
        • 5.2.5.2. Academic Research Organizations & Institutes
        • 5.2.5.3. Others
      • 5.2.6. Global Bacteriophages Therapy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Bacteriophages Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Armata Pharmaceuticals, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. INtODEWORLD, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Phage International, Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Fixed-Phage Limited (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. LOCUS BIOSCIENCES, INC (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pherecydes Pharma (French)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Adaptive Phage Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Intralytix, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. PhagoMed Biopharma GmbH (Austria)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PHAGELUX, INC (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bacteriophages Therapy Sale, by Type, Application, Treatment, Specifications, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Bacteriophages Therapy (Value)
      • 7.2.1. Global Bacteriophages Therapy by: Type (Value)
        • 7.2.1.1. Lytic
        • 7.2.1.2. Lysogenic
      • 7.2.2. Global Bacteriophages Therapy by: Application (Value)
        • 7.2.2.1. Diagnostic
        • 7.2.2.2. Antimicrobial Drug Discovery
        • 7.2.2.3. Veterinary Medicines
        • 7.2.2.4. Others
      • 7.2.3. Global Bacteriophages Therapy by: Treatment (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. External Application
        • 7.2.3.3. Surgical Treatment
      • 7.2.4. Global Bacteriophages Therapy by: Specifications (Value)
        • 7.2.4.1. Human Medicine
        • 7.2.4.2. Veterinary Science
        • 7.2.4.3. Agriculture
      • 7.2.5. Global Bacteriophages Therapy by: End User (Value)
        • 7.2.5.1. Hospitals & Clinics
        • 7.2.5.2. Academic Research Organizations & Institutes
        • 7.2.5.3. Others
      • 7.2.6. Global Bacteriophages Therapy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bacteriophages Therapy: by Type(USD Million)
  • Table 2. Bacteriophages Therapy Lytic , by Region USD Million (2017-2022)
  • Table 3. Bacteriophages Therapy Lysogenic , by Region USD Million (2017-2022)
  • Table 4. Bacteriophages Therapy: by Application(USD Million)
  • Table 5. Bacteriophages Therapy Diagnostic , by Region USD Million (2017-2022)
  • Table 6. Bacteriophages Therapy Antimicrobial Drug Discovery , by Region USD Million (2017-2022)
  • Table 7. Bacteriophages Therapy Veterinary Medicines , by Region USD Million (2017-2022)
  • Table 8. Bacteriophages Therapy Others , by Region USD Million (2017-2022)
  • Table 9. Bacteriophages Therapy: by Treatment(USD Million)
  • Table 10. Bacteriophages Therapy Oral , by Region USD Million (2017-2022)
  • Table 11. Bacteriophages Therapy External Application , by Region USD Million (2017-2022)
  • Table 12. Bacteriophages Therapy Surgical Treatment , by Region USD Million (2017-2022)
  • Table 13. Bacteriophages Therapy: by Specifications(USD Million)
  • Table 14. Bacteriophages Therapy Human Medicine , by Region USD Million (2017-2022)
  • Table 15. Bacteriophages Therapy Veterinary Science , by Region USD Million (2017-2022)
  • Table 16. Bacteriophages Therapy Agriculture , by Region USD Million (2017-2022)
  • Table 17. Bacteriophages Therapy: by End User(USD Million)
  • Table 18. Bacteriophages Therapy Hospitals & Clinics , by Region USD Million (2017-2022)
  • Table 19. Bacteriophages Therapy Academic Research Organizations & Institutes , by Region USD Million (2017-2022)
  • Table 20. Bacteriophages Therapy Others , by Region USD Million (2017-2022)
  • Table 21. South America Bacteriophages Therapy, by Country USD Million (2017-2022)
  • Table 22. South America Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 23. South America Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 24. South America Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 25. South America Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 26. South America Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 27. Brazil Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 28. Brazil Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 29. Brazil Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 30. Brazil Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 31. Brazil Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 32. Argentina Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 33. Argentina Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 34. Argentina Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 35. Argentina Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 36. Argentina Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 37. Rest of South America Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 38. Rest of South America Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 39. Rest of South America Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 40. Rest of South America Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 41. Rest of South America Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 42. Asia Pacific Bacteriophages Therapy, by Country USD Million (2017-2022)
  • Table 43. Asia Pacific Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 44. Asia Pacific Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 45. Asia Pacific Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 46. Asia Pacific Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 47. Asia Pacific Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 48. China Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 49. China Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 50. China Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 51. China Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 52. China Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 53. Japan Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 54. Japan Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 55. Japan Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 56. Japan Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 57. Japan Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 58. India Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 59. India Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 60. India Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 61. India Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 62. India Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 63. South Korea Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 64. South Korea Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 65. South Korea Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 66. South Korea Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 67. South Korea Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 68. Taiwan Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 69. Taiwan Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 70. Taiwan Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 71. Taiwan Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 72. Taiwan Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 73. Australia Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 74. Australia Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 75. Australia Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 76. Australia Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 77. Australia Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 78. Rest of Asia-Pacific Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 79. Rest of Asia-Pacific Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 80. Rest of Asia-Pacific Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 81. Rest of Asia-Pacific Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 83. Europe Bacteriophages Therapy, by Country USD Million (2017-2022)
  • Table 84. Europe Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 85. Europe Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 86. Europe Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 87. Europe Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 88. Europe Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 89. Germany Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 90. Germany Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 91. Germany Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 92. Germany Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 93. Germany Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 94. France Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 95. France Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 96. France Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 97. France Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 98. France Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 99. Italy Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 100. Italy Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 101. Italy Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 102. Italy Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 103. Italy Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 104. United Kingdom Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 105. United Kingdom Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 106. United Kingdom Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 107. United Kingdom Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 108. United Kingdom Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 109. Netherlands Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 110. Netherlands Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 111. Netherlands Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 112. Netherlands Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 113. Netherlands Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 114. Rest of Europe Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 115. Rest of Europe Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 116. Rest of Europe Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 117. Rest of Europe Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 118. Rest of Europe Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 119. MEA Bacteriophages Therapy, by Country USD Million (2017-2022)
  • Table 120. MEA Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 121. MEA Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 122. MEA Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 123. MEA Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 124. MEA Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 125. Middle East Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 126. Middle East Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 127. Middle East Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 128. Middle East Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 129. Middle East Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 130. Africa Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 131. Africa Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 132. Africa Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 133. Africa Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 134. Africa Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 135. North America Bacteriophages Therapy, by Country USD Million (2017-2022)
  • Table 136. North America Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 137. North America Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 138. North America Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 139. North America Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 140. North America Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 141. United States Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 142. United States Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 143. United States Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 144. United States Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 145. United States Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 146. Canada Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 147. Canada Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 148. Canada Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 149. Canada Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 150. Canada Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 151. Mexico Bacteriophages Therapy, by Type USD Million (2017-2022)
  • Table 152. Mexico Bacteriophages Therapy, by Application USD Million (2017-2022)
  • Table 153. Mexico Bacteriophages Therapy, by Treatment USD Million (2017-2022)
  • Table 154. Mexico Bacteriophages Therapy, by Specifications USD Million (2017-2022)
  • Table 155. Mexico Bacteriophages Therapy, by End User USD Million (2017-2022)
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Bacteriophages Therapy: by Type(USD Million)
  • Table 167. Bacteriophages Therapy Lytic , by Region USD Million (2023-2028)
  • Table 168. Bacteriophages Therapy Lysogenic , by Region USD Million (2023-2028)
  • Table 169. Bacteriophages Therapy: by Application(USD Million)
  • Table 170. Bacteriophages Therapy Diagnostic , by Region USD Million (2023-2028)
  • Table 171. Bacteriophages Therapy Antimicrobial Drug Discovery , by Region USD Million (2023-2028)
  • Table 172. Bacteriophages Therapy Veterinary Medicines , by Region USD Million (2023-2028)
  • Table 173. Bacteriophages Therapy Others , by Region USD Million (2023-2028)
  • Table 174. Bacteriophages Therapy: by Treatment(USD Million)
  • Table 175. Bacteriophages Therapy Oral , by Region USD Million (2023-2028)
  • Table 176. Bacteriophages Therapy External Application , by Region USD Million (2023-2028)
  • Table 177. Bacteriophages Therapy Surgical Treatment , by Region USD Million (2023-2028)
  • Table 178. Bacteriophages Therapy: by Specifications(USD Million)
  • Table 179. Bacteriophages Therapy Human Medicine , by Region USD Million (2023-2028)
  • Table 180. Bacteriophages Therapy Veterinary Science , by Region USD Million (2023-2028)
  • Table 181. Bacteriophages Therapy Agriculture , by Region USD Million (2023-2028)
  • Table 182. Bacteriophages Therapy: by End User(USD Million)
  • Table 183. Bacteriophages Therapy Hospitals & Clinics , by Region USD Million (2023-2028)
  • Table 184. Bacteriophages Therapy Academic Research Organizations & Institutes , by Region USD Million (2023-2028)
  • Table 185. Bacteriophages Therapy Others , by Region USD Million (2023-2028)
  • Table 186. South America Bacteriophages Therapy, by Country USD Million (2023-2028)
  • Table 187. South America Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 188. South America Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 189. South America Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 190. South America Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 191. South America Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 192. Brazil Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 193. Brazil Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 194. Brazil Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 195. Brazil Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 196. Brazil Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 197. Argentina Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 198. Argentina Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 199. Argentina Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 200. Argentina Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 201. Argentina Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 202. Rest of South America Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 203. Rest of South America Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 204. Rest of South America Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 205. Rest of South America Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 206. Rest of South America Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 207. Asia Pacific Bacteriophages Therapy, by Country USD Million (2023-2028)
  • Table 208. Asia Pacific Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 209. Asia Pacific Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 210. Asia Pacific Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 211. Asia Pacific Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 212. Asia Pacific Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 213. China Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 214. China Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 215. China Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 216. China Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 217. China Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 218. Japan Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 219. Japan Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 220. Japan Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 221. Japan Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 222. Japan Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 223. India Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 224. India Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 225. India Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 226. India Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 227. India Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 228. South Korea Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 229. South Korea Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 230. South Korea Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 231. South Korea Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 232. South Korea Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 233. Taiwan Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 234. Taiwan Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 235. Taiwan Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 236. Taiwan Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 237. Taiwan Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 238. Australia Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 239. Australia Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 240. Australia Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 241. Australia Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 242. Australia Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 243. Rest of Asia-Pacific Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 244. Rest of Asia-Pacific Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 245. Rest of Asia-Pacific Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 246. Rest of Asia-Pacific Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 247. Rest of Asia-Pacific Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 248. Europe Bacteriophages Therapy, by Country USD Million (2023-2028)
  • Table 249. Europe Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 250. Europe Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 251. Europe Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 252. Europe Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 253. Europe Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 254. Germany Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 255. Germany Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 256. Germany Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 257. Germany Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 258. Germany Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 259. France Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 260. France Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 261. France Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 262. France Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 263. France Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 264. Italy Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 265. Italy Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 266. Italy Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 267. Italy Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 268. Italy Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 269. United Kingdom Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 270. United Kingdom Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 271. United Kingdom Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 272. United Kingdom Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 273. United Kingdom Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 274. Netherlands Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 275. Netherlands Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 276. Netherlands Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 277. Netherlands Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 278. Netherlands Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 279. Rest of Europe Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 280. Rest of Europe Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 281. Rest of Europe Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 282. Rest of Europe Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 283. Rest of Europe Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 284. MEA Bacteriophages Therapy, by Country USD Million (2023-2028)
  • Table 285. MEA Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 286. MEA Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 287. MEA Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 288. MEA Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 289. MEA Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 290. Middle East Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 291. Middle East Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 292. Middle East Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 293. Middle East Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 294. Middle East Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 295. Africa Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 296. Africa Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 297. Africa Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 298. Africa Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 299. Africa Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 300. North America Bacteriophages Therapy, by Country USD Million (2023-2028)
  • Table 301. North America Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 302. North America Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 303. North America Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 304. North America Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 305. North America Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 306. United States Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 307. United States Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 308. United States Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 309. United States Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 310. United States Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 311. Canada Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 312. Canada Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 313. Canada Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 314. Canada Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 315. Canada Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 316. Mexico Bacteriophages Therapy, by Type USD Million (2023-2028)
  • Table 317. Mexico Bacteriophages Therapy, by Application USD Million (2023-2028)
  • Table 318. Mexico Bacteriophages Therapy, by Treatment USD Million (2023-2028)
  • Table 319. Mexico Bacteriophages Therapy, by Specifications USD Million (2023-2028)
  • Table 320. Mexico Bacteriophages Therapy, by End User USD Million (2023-2028)
  • Table 321. Research Programs/Design for This Report
  • Table 322. Key Data Information from Secondary Sources
  • Table 323. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bacteriophages Therapy: by Type USD Million (2017-2022)
  • Figure 5. Global Bacteriophages Therapy: by Application USD Million (2017-2022)
  • Figure 6. Global Bacteriophages Therapy: by Treatment USD Million (2017-2022)
  • Figure 7. Global Bacteriophages Therapy: by Specifications USD Million (2017-2022)
  • Figure 8. Global Bacteriophages Therapy: by End User USD Million (2017-2022)
  • Figure 9. South America Bacteriophages Therapy Share (%), by Country
  • Figure 10. Asia Pacific Bacteriophages Therapy Share (%), by Country
  • Figure 11. Europe Bacteriophages Therapy Share (%), by Country
  • Figure 12. MEA Bacteriophages Therapy Share (%), by Country
  • Figure 13. North America Bacteriophages Therapy Share (%), by Country
  • Figure 14. Global Bacteriophages Therapy share by Players 2022 (%)
  • Figure 15. Global Bacteriophages Therapy share by Players (Top 3) 2022(%)
  • Figure 16. Global Bacteriophages Therapy share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Armata Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Armata Pharmaceuticals, Inc (United States) Revenue: by Geography 2022
  • Figure 20. INtODEWORLD, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 21. INtODEWORLD, Inc (United States) Revenue: by Geography 2022
  • Figure 22. Phage International, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 23. Phage International, Inc (United States) Revenue: by Geography 2022
  • Figure 24. Fixed-Phage Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Fixed-Phage Limited (United Kingdom) Revenue: by Geography 2022
  • Figure 26. LOCUS BIOSCIENCES, INC (United States) Revenue, Net Income and Gross profit
  • Figure 27. LOCUS BIOSCIENCES, INC (United States) Revenue: by Geography 2022
  • Figure 28. Pherecydes Pharma (French) Revenue, Net Income and Gross profit
  • Figure 29. Pherecydes Pharma (French) Revenue: by Geography 2022
  • Figure 30. Adaptive Phage Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 31. Adaptive Phage Therapeutics (United States) Revenue: by Geography 2022
  • Figure 32. Intralytix, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. Intralytix, Inc (United States) Revenue: by Geography 2022
  • Figure 34. PhagoMed Biopharma GmbH (Austria) Revenue, Net Income and Gross profit
  • Figure 35. PhagoMed Biopharma GmbH (Austria) Revenue: by Geography 2022
  • Figure 36. PHAGELUX, INC (China) Revenue, Net Income and Gross profit
  • Figure 37. PHAGELUX, INC (China) Revenue: by Geography 2022
  • Figure 38. Global Bacteriophages Therapy: by Type USD Million (2023-2028)
  • Figure 39. Global Bacteriophages Therapy: by Application USD Million (2023-2028)
  • Figure 40. Global Bacteriophages Therapy: by Treatment USD Million (2023-2028)
  • Figure 41. Global Bacteriophages Therapy: by Specifications USD Million (2023-2028)
  • Figure 42. Global Bacteriophages Therapy: by End User USD Million (2023-2028)
  • Figure 43. South America Bacteriophages Therapy Share (%), by Country
  • Figure 44. Asia Pacific Bacteriophages Therapy Share (%), by Country
  • Figure 45. Europe Bacteriophages Therapy Share (%), by Country
  • Figure 46. MEA Bacteriophages Therapy Share (%), by Country
  • Figure 47. North America Bacteriophages Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Armata Pharmaceuticals, Inc (United States)
  • iNtODEWORLD, Inc (United States)
  • Phage International, Inc (United States)
  • Fixed-Phage Limited (United Kingdom)
  • LOCUS BIOSCIENCES, INC (United States)
  • Pherecydes Pharma (French)
  • Adaptive Phage Therapeutics (United States)
  • Intralytix, Inc (United States)
  • PhagoMed Biopharma GmbH (Austria)
  • PHAGELUX, INC (China)
Select User Access Type

Key Highlights of Report


Jun 2023 227 Pages 85 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bacteriophages Therapy Market Quantitative research analysis
Global Bacteriophages Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Bacteriophages Therapy Market are Armata Pharmaceuticals, Inc (United States), iNtODEWORLD, Inc (United States), Phage International, Inc (United States), Fixed-Phage Limited (United Kingdom), LOCUS BIOSCIENCES, INC (United States), Pherecydes Pharma (French), Adaptive Phage Therapeutics (United States), Intralytix, Inc (United States), PhagoMed Biopharma GmbH (Austria) and PHAGELUX, INC (China) etc.
Diagnostic segment in Global market to hold robust market share owing to "Growing need for therapeutic Bacteriophages therapy they have advantages over antibiotics ".

Know More About Global Bacteriophages Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Systemic Mycoses Comprehensive Study by Type (Paracoccidioides, Blastomyces, Histoplasma, Coccidiode), Fungi (Dermatophytes, Yeasts, Molds), Drugs (Amphotericin B, Amphotericin B Itraconazole, Amphot...
$ 3750
Neurotrophic Keratitis Treatment Comprehensive Study by Type (Drugs, Devices, Surgery), Application (Hospitals, Ambulatory Surgical Centers, Others), Route of Administration (Oral, Topical), Distribu...
$ 3450
Metastatic Bone Disease Treatment Comprehensive Study by Type (Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy), Application (Hospitals, Specialty Clinics, Ambulatory Sur...
$ 3750
Digital Brain Therapy Comprehensive Study by Type (Transcranial random noise stimulation (tRNS), Transcranial direct current stimulation (tDCS), Transcranial alternating current stimulation (tACS), T...
$ 3750
Dementia Care Comprehensive Study by Type (Memory Exercise & Activity Products, Daily Reminder Products, Bathroom Safety Products, Dining Aids Communication Products, Personal Safety Products Others)...
$ 3450
Stress Relief Supplements Comprehensive Study by Application (Hospitals, Clinics, Others), Nature (Natural/Herbal Based, Chemical Based), Distribution Channel (Online, Offline (Pharmacies Supermarket...
$ 3450